

Identification of two novel PNPLA1 mutations in Turkish families with autosomal recessive congenital ichthyosis

Serap Dökmeci-Emre¹, Zihni Ekim Taşkiran², Ayşe Yüzbaşıoğlu^{1,3}, Gizem Önal¹, Ayşe Nurten Akarsu², Ayşen Karaduman⁴, Meral Özgüç^{1,3}

¹Department of Medical Biology, ²Department of Medical Genetics, ³Department of Medical Biology and Center for Biobanking and Genomics, ⁴Department of Dermatology and Venereology, Hacettepe University Faculty of Medicine, Ankara, Turkey.
E-mail: semre@hacettepe.edu.tr

Received: 28th March 2017, Accepted: 30th July 2017

SUMMARY: Dökmeci-Emre S, Taşkiran ZE, Yüzbaşıoğlu A, Önal G, Akarsu AN, Karaduman A, Özgüç M. Identification of two novel PNPLA1 mutations in Turkish families with autosomal recessive congenital ichthyosis. Turk J Pediatr 2017; 59: 475-482.

Autosomal recessive congenital ichthyosis (ARCI) is a group of inherited keratinization disorders that are characterized by abnormal epidermal keratinization. ARCI patients generally represent serious symptoms including collodion baby phenotype accompanied by dehydration, heat loss, electrolytic imbalance, and sepsis. ARCI shows high degree of clinical and genetic heterogeneity. To date, nine genes were shown to be responsible for ARCI phenotype. One of these genes, patatin-like phospholipase domain containing protein-1 (PNPLA1) was suggested to be involved in the synthesis of ω -O-acylceramides related to epidermal cornified lipid envelope organization. In addition to previously reported PNPLA1 mutations, we report two novel PNPLA1 mutations including one novel missense mutation c.335C>A (p.Ser112Tyr) and one novel deletion mutation c.733_735delTAC (p.Tyr245del) in Turkish ARCI patients from unrelated consanguineous families. We also report previously reported missense mutation c.514G>A (p.Asp172Asn) in Turkish ARCI patients. Novel PNPLA1 mutations were shown to be located in the catalytic patatin domain of PNPLA1 gene. Identification of novel mutations in PNPLA1 gene expands the mutational spectrum in the causative gene. Increase in the total number of cases has high diagnostic value in terms of genotype-phenotype correlation in ARCI patients.

Key words: autosomal recessive congenital ichthyosis (ARCI), PNPLA1, mutation.

Autosomal recessive congenital ichthyosis (ARCI) comprises a group of clinically and genetically heterogeneous Mendelian disorders of cornification (MEDOC) with a prevalence of less than 1/200.000.^{1,2} ARCI is mainly characterized by abnormal scaling over the whole body due to the defects in epidermal keratinocyte differentiation and lipid metabolism.^{3,4} The molecular mechanisms of ARCI are related to functional defects in the major components of epidermal barrier including intercellular lipid barrier, the cornified cell envelope and keratin or filaggrin degradation products.⁵ The symptoms of ARCI may vary from mild to lethal conditions including hydroelectrolytic imbalance, thermal instability, dehydration,

collodion baby phenotype and infection.^{2,4} To date, nine different genes including TGM1^{6,7}, ABCA12⁸, ALOXE3⁹, ALOX12B⁹⁻¹¹, CYP4F22¹², LIPN¹³, NIPAL4¹⁴, CERS3^{15,16}, and PNPLA1¹⁷ were found to be associated with ARCI.

Patatin-like phospholipase domain containing 1 (PNPLA1) gene (Gene ID 285848) is defined as one of the ARCI causing genes.¹⁷ PNPLA1 gene contains eight exons at chromosome 6p21.31. The cloned cDNA sequence is 1,599 bp. (GenBank accession No. FJ457781) encoding a polypeptide with 532 amino acids. PNPLA1 protein has a patatin domain (residues 16–185) in the N-terminal region with serine–aspartate catalytic dyad (S53-D172) and a proline-rich domain (residues 326–451) in the C-terminal

region.¹⁸ Mammalian patatin-like phospholipase domain containing protein family (PNPLA1-9) have critical roles in diverse aspects of signaling pathways and lipid metabolism involving triglyceride lipase, hydrolase, and transacylase activities.^{19,20} It is reported that human PNPLA1 protein is predominantly expressed in the keratinocytes of epidermal granular layer and plays role in lipid metabolism associated with cutaneous barrier formation.¹⁷ In addition, recent studies reported that PNPLA1 function in the synthesis of omega-O-acylceramides as a transacylase and affect epidermal cornified lipid envelope organization.²¹⁻²³

To date, 26 different PNPLA1 mutations have been reported associated with ARCI.^{17, 24-27,30} In the present study, we report two novel mutations, including one missense mutation c.335C>A (p.Ser112Tyr) and one deletion mutation c.733_735delTAC (p.Tyr245del), and also one previously reported missense mutation c.514G>A (p.Asp172Asn) in PNPLA1 gene in seven ARCI patients from three consanguineous Turkish families.

Case Report

Seven patients from three consanguineous families were recruited (Fig. 1). The diagnosis of all patients was made by of clinical findings and histopathological features of skin biopsies. All detailed clinical findings are summarized in Table I. This study was approved by the Ethics Committee of Hacettepe University and informed consent to participate was obtained from all patients and/or parents.

Genotype analysis of selected individuals from a cohort of three consanguineous families with ARCI was achieved using genome-wide linkage analysis and Sanger DNA sequencing methods. Affymetrix 250K SNP arrays were used in order to perform genome-wide analysis according to manufacturer's recommendations. VIGENOS Software (Hemosoft, Ankara) was used for homozygosity mapping. The affected individuals showed a homozygous haplotype in the 6p21 region comprising PNPLA1 gene. Both DNA strands from the probands were entirely sequenced for the eight exons and for the intron/exon boundaries of the PNPLA1 gene. Details of PCR procedure were previously




Fig. 1. Pedigree drawings of three consanguineous families with ARCI.

Table I. Summary of Clinical Features.

Family	Sex	Age	Collodion baby	Distribution of scaling	Scale	Erythema	Ectropion	Scalp	Palmoplantar involvement	Hypohidrosis	Nail/teeth	Pruritus
I	M	20 yrs.	+	Generalized, including flexures	White-light brown, large lamellar	Mild, generalized	-	No	Mild palmoplantar keratoderma, accentuated palmoplantar markings	-	-/-	Mild
I	M	2 mo.	+	Generalized, including flexures	Mild-severe generalized lamellar; octagonal lamellar on the back and legs	Mild, generalized	+	No	Mild palmoplantar keratoderma	-	-/-	Mild
II	F	8 yrs.	+	Generalized, including flexures	White-light brown, mild to moderate	Mild to moderate; face	+	Squamous pityriasisiform appearance	Mild palmoplantar keratoderma, accentuated palmoplantar markings	-	-/-	Mild
II	M	5 yrs.	+	Generalized, including flexures	White-light brown	Mild to moderate; face	+	Squamous pityriasisiform appearance	Mild palmoplantar keratoderma	+	-/-	Mild
II	F	5 yrs.	+	Generalized, including flexures	White-light brown	Mild to moderate; face	+	Thick scale	Mild palmoplantar keratoderma	-	+/-	Mild
III	F	2 yrs.	+	Generalized, including flexures	White-gray, mild to moderate	Disseminated, mild	+	Squamous pityriasisiform appearance	Accentuated palmoplantar markings	-	+/+	Mild
III	F	20 days	+	-	White, fine	+	+	-	Accentuated palmoplantar markings	-	-/-	-

described.¹⁷ Cycle sequencing was performed with the ABI PRISM Big Dye Terminator Cycle Sequencing Kit following the manufacturer's instructions and sequences were analyzed on the ABI PRISM 3130 DNA Analyzer. All parents were heterozygous for the mutations. Following the analysis of the patients and their relatives, it was shown that identified novel mutations co-segregated with their ARCI status. No mutations in the PNPLA1 gene were detected in a panel of 100 control DNA samples.

Family 1: Two affected patients from a consanguineous family (Family I), born as collodion babies presented with skins with generalized fine white to light-brown scales underlying erythema base. There was a mild palmoplantar keratoderma and hyperlinearity. One of the patients (III:5) had mild to severe large scales on the back. The other patient (IV:3) had mild to severe octagonal scales on the back and legs. Their nails and teeth were normal.

In this family, two affected individuals had a homozygous missense mutation (c.514G>A) in exon 4 of the PNPLA1 gene, which resulted in a G to A transition in the cDNA at position 514 downstream of the start codon (Fig. 2a). The mutation results in replacement of aspartate with asparagine at position 172 (p.Asp172Asn). The missense mutation p.Asp172Asn is localized at the site of serine-aspartate catalytic dyad (S53-D172) in the patatin domain. The mutations in PNPLA1 were modeled by using SWISS_MODEL (<http://swissmodel.expasy.org>) (Fig. 3). The exchange of an acidic amino acid aspartate with a uncharged amino acid glutamine at the position 172 may potentially disturb catalytic activity of the patatin domain (Fig. 3a).

Family 2: Three affected patients (II:1, II:3, II:4), diagnosed at ages 8, 5 and 5 respectively, from a consanguineous family (Family II), born as collodion babies and they had mild to moderate erythema on the face. Their skin presented generalized fine small, white and light brown scales. In flexures, brown linear thick plaques were seen. Similar lesions were present on the dorsum of hand and feet. They had palmoplantar keratoderma, pruritus and nail abnormality including toenail dystrophy and distal onycholysis. They had squamous pityriasiform appearance on the scalp. All

patients in the family had large-octagonal scales on the legs.

The three affected individuals were found to have a novel homozygous deletion mutation (c.733_735delTAC) in exon 5 of the PNPLA1 gene (Fig. 2b). This mutation causes the deletion of the tyrosine residue at position 245 (p.Tyr245del). Deletion of a tyrosine amino acid may cause an alteration in the alpha helix structure that most probably alters PNPLA1 protein folding (Fig. 3b). The pathogenicity of identified mutations was evaluated by using prediction programs PolyPhen-2, SIFT and PROVEAN (Protein Variation Effect Analyzer). According to pathogenicity prediction programs, it was predicted that the p.Tyr245del mutation has deleterious effect on the function of the PNPLA1 protein. (Table II)

Family 3: Two affected sisters from a consanguineous family (Family III), born as collodion babies. One of the sisters (II:3) with similar findings to other sister died at eight months of age. The other sister (II:2) had diffuse erythema and white gray scales on her whole body. She had hyperkeratotic plaques on the knees, elbows and back of the neck. Thick dystrophic nails and brown teeth were observed. She had squamous pityriasiform appearance on the scalp.

The patients in the family were found to have novel c.335C>A mutation in PNPLA1 gene (Figure 2C). This mutation is located in the patatin domain which replaced a serine residue with a tyrosine at amino acid position 112 (p.Ser112Tyr). The exchange of hydroxyl side group of serine with aromatic side group of tyrosine may disrupt protein folding and affect catalytic patatin domain activity (Fig. 3c). p.Ser112Tyr was also predicted to have deleterious functional effects in PNPLA1 protein (Table II).

Discussion

This report and previous studies revealed that PNPLA1 mutations lead to various ARCI symptoms including collodion baby phenotype, generalized mild to severe scales with flexures, mild to moderate erythema, pruritus and palmoplantar keratoderma. We have not defined any unique ARCI symptom specific for PNPLA1 mutations. Clinical findings of our ARCI patients were commonly similar to previously




Fig. 2. Electropherograms showing the nucleotide sequence of a healthy individual (upper panels) and homozygous affected members (lower panels) with mutations (A) c.514G>A, (B) c.733_735delTAC and (C) c.335C>A.




Fig. 3. 3D structure of mutated amino acid residues for mutations (A) c.514G>A, (B) c.733_735delTAC and (C) c.335C>A are shown. The models were obtained from SWISS-MODEL (<http://swissmodel.expasy.org/>).




Fig. 4. The structure of PNPLA1 gene and PNPLA1 protein. PNPLA1 mutations identified by this report are shown on the gene structure.

Table II. List of Mutations Reported in the PNPLA1 Gene.

Alleles	Nucleotide change	Aminoacid change	Variation type	Ethnic origin	Reported previously by	Poly-Phen-2.1 (HumVar)	SIFT	PROVEAN
Homozygous	c.335C>A	p.Ser112Tyr	Missense	Turkish	This report	0.877	0.01	-3,314
Homozygous	c.733_735delTTAC	p.Tyr245del	Deletion	Turkish	This report	-	-	-10,006
Homozygous	c.514G>A	p.Asp172Asn	Missense	Lurish, Azeri	Vahidnezhad et al., 2016	0.988	0.01	-4,995
Homozygous	c.176C>T	p.Ala59Val	Missense	Kazakh	Zimmer et. al., 2017	-	-	-
Homozygous	c.391G>T	p.Glu131	Nonsense	Morocco	Grall et. al. , 2012	1	0.02	-3,126
Homozygous	c.100G>A	p.Ala34Thr	Missense	Algeria	Grall et. al. , 2012	-	-	-
Homozygous	c.387C>A	p.Asp129Glu	Missense	Spanish	Fachal et. al., 2014	0.979	0.02	-1,729
Homozygous	c.56C>T	p.Ser19Leu	Missense	Pakistani	Ahmad et. al., 2015	1	0.02	-3,930
Homozygous	c.100G>C	p.Ala34Pro	Missense	Pakistan	Lee et. al., 2016	-	-	-
Homozygous	c.374C>A	p.Thr125Asn	Missense	Persian	Vahidnezhad et al. 2016	1	0	-3,284
Homozygous	c.421A>G	p.Lys141Glu	Missense	Lurish	Vahidnezhad et al. 2016	1	0.01	-3,229
Homozygous	c.488.C>T	p.Pro163Leu	Missense	Persian	Vahidnezhad et al. 2016	1	0	-4,829
Homozygous	c.535C>T	p.Gln179*	Nonsense	Kurdish, Persian	Vahidnezhad et al. 2016	0.982	0.02	-3,644
Compound heterozygous	c.88G>A	p.Gly30Arg	Missense	Arab	Vahidnezhad et al. 2016	-	0.07	-10,000
Compound heterozygous	c.418T>C	p.Ser140Pro	Missense	Unknown	Zimmer et. al., 2017	-	-	-
Compound heterozygous	c.418T>C	p.Ser140Pro	Missense	French	Zimmer et. al., 2017	1	0	-7,348
Compound heterozygous	c.421A>G	p.Lys141Glu	Missense	French	Zimmer et. al., 2017	0.957	0.002	-4,636
Compound heterozygous	c.311T>C	p.Leu104Pro	Missense	French	Zimmer et. al., 2017	0.957	0.002	-4,636
Compound heterozygous	c.1143delC	p.Ser382Alafs*74	Deletion	French	Zimmer et. al., 2017	0.982	0.001	-3,644
Compound heterozygous	c.121delC	p.Arg41Glyfs*17	Deletion	French	Zimmer et. al., 2017	0.215	0.052	-6,510
Compound heterozygous	c.667G>A	p.Glu223Lys	Missense	Unknown	Zimmer et. al., 2017	-	-	-
Compound heterozygous	c.275delC	p.Pro92Argfs*8	Deletion	Unknown	Zimmer et. al., 2017	-	-	-
Compound heterozygous	c.775+3A>T		Splice Site	Unknown	Zimmer et. al., 2017	-	-	-
Homozygous	c.704delC	p.Pro235Argfs*4	Deletion	German/Italian?	Zimmer et. al., 2017	0.983	0.051	-1,470
Compound heterozygous	c.434T>C	p.Ile145Thr	Missense	German?	Zimmer et. al., 2017	-	-	-
Compound heterozygous	c.536A>G	p.Gln179Arg	Missense	German?	Zimmer et. al., 2017	-	-	-1,734
Compound heterozygous	c.158C>T	p.Ser53Leu	Missense	Pakistani	Zimmer et. al., 2017	1	0.009	-5,507
Compound heterozygous	c.301A>G	p.Arg101Gly	Missense	Pakistani	Zimmer et. al., 2017	0.968	0.001	-5,969
Compound heterozygous	c.275delC	p.Pro92Argfs*8	Deletion	Unknown	Zimmer et. al., 2017	-	-	-
Homozygous	c.496C>T	p.Arg166Cys	Missense	French	Zimmer et. al., 2017	1	0	-7,302

reported symptoms.²⁵ Generally, the symptoms of ARCI patients with PNPLA1 mutations are relatively milder than the other forms of ARCI especially caused by TGM1 and ABCA12 mutations.²⁵

ARCI causing genes play important roles in differentiation of epidermal keratinocytes and/or formation of epidermal lipid barrier. Previously, ARCI causing genes CERS3, ALOX12B, CYP4F22 and ALOXE3 were reported to play role in ceramide metabolism during epidermal lipid barrier formation.^{28,29} Recently, PNPLA1 protein was reported to play role in acylceramide synthesis by catalyzing esterification of omega-hydroxyceramide with linoleic acid in epidermal cornified envelope formation.²¹⁻²³ As PNPLA1 protein plays important role in epidermal lipid barrier formation, mutations in PNPLA1 gene lead to ARCI pathology.

p.Asp172Asn mutation that we identified in 2 ARCI patients in a Turkish consanguineous family was previously reported by Zimmer A et al.²⁵ and Vahidnezhad H et al.³⁰ in Kazakh, Azeri and Lurish patients. This mutation is located at the catalytic site of PNPLA1 as Ser53 and Asp172 form catalytic dyad of patatin domain. Zimmer A et al.²⁵ had also reported homozygous p.Ser53Leu mutation that is located at the position of Serine 53 of catalytic dyad in patatin domain. The pathogenic mutations located at catalytic site of the protein appears frequently in ARCI patients from different ethnic background.

p.Ser112Tyr mutation which is also located at patatin domain of the protein is the novel mutation reported first time in this report. Two Turkish ARCI patients had homozygous p.Ser112Tyr mutation in a consanguineous family and this mutation probably impairs functionality of PNPLA1 and leads to ARCI pathology. In addition, we report a novel deletion mutation p.Tyr245del which leads to deletion of a tyrosine amino acid at position 245. Actually, the p.Tyr245del mutation is located between core patatin domain and proline rich domain of PNPLA1 gene. Recently, it was suggested that in addition to core patatin domain PNPLA1 protein may have a functional extended patatin domain involving N terminal residues 1-288.²⁵ Consistently, the p.Tyr245del mutation is exactly located at the

extended patatin domain of the protein. Clinical findings of our ARCI patients reveal that the p.Tyr245del mutation in the extended patatin domain may be relevant to PNPLA1 function.

To date, twenty-six mutations in PNPLA1 gene were identified in ARCI patients from a cohort of families from various ethnic background including African-Czech, German, Swedish, Algeria, French, Pakistani Kazakh, Spanish, Morocco, Persian, Lurish, Kurdish, Arab and Azeri.^{17, 24-27,30} In this study, we report novel PNPLA1 mutations identified for the first time in Turkish ARCI patients. All PNPLA1 mutations identified in ARCI patients were summarized in Table II. Nearly all reported PNPLA1 mutations including our results are localized in the core patatin domain or extended patatin domain (Fig. 4). The other mutations located outside of patatin domain lead to early stop codon and form truncated protein which cause either loss of PNPLA1 functionality or change intracellular localization of protein. So, extended patatin domain is a disease causing mutation hot spot in the PNPLA1 gene and this domain is essential for functionality of the gene. Moreover, since almost all reported gene variations reside in the patatin domain, it draws almost all attention to functional sequence and its effect on the dysfunction of the epidermal keratinocytes.

It was assumed that the frequency of PNPLA1 mutations among ARCI patients is approximately 3%.²⁵ ARCI is a very rare genetic disease and in this case differential analysis has high diagnostic value. The increase in frequency and spectrum of PNPLA1 mutations show the necessity of PNPLA1 mutation analysis in ARCI patients especially in newborns with ichthyosis.

Acknowledgments

We wish to thank the members of the families for their invaluable cooperation and participation in this study.

REFERENCES

1. Oji V, Tadini G, Akiyama M, et al. Revised nomenclature and classification of inherited ichthyosis: Results of the First Ichthyosis Consensus Conference in Soreze 2009. *J Am Acad Dermatol* 2010; 63: 607-641.
2. Richard G, Bale SJ. Autosomal recessive congenital ichthyosis. In: Pagon RA, Bird TD, Dolan CR, et al. (eds). *GeneReviews*. Seattle (WA): University of Washington, Seattle, 2014.

3. Elias PM, Williams ML, Holleran WM, Jiang YJ, Schmuth M. Pathogenesis of permeability barrier abnormalities in the ichthyoses: Inherited disorders of lipid metabolism. *J Lipid Res* 2008; 49: 697-714.
4. Rodriguez-Pazos L, Ginarte M, Vega A, Toribio J. Autosomal recessive congenital ichthyosis. *Actas Dermosifiliogr* 2013; 104: 270-284.
5. Akiyama M, Shimizu H. An update on molecular aspects of the non-syndromic ichthyoses. *Exp Dermatol* 2008; 17: 373-382.
6. Huber M, Rettler I, Bernasconi K, et al. Mutations of keratinocyte transglutaminase in lamellar ichthyosis. *Science* 1995; 267: 525-528.
7. Russell LJ, DiGiovanna JJ, Rogers GR, et al. Mutations in the gene for transglutaminase 1 in autosomal recessive lamellar ichthyosis. *Nat Genet* 1995; 9: 279-283.
8. Lefèvre C, Audebert S, Jobard F, et al. Mutations in the transporter ABCA12 are associated with lamellar ichthyosis type 2. *Hum Mol Genet* 2003; 12: 2369-2378.
9. Jobard F, Lefèvre C, Karaduman A, et al. Lipoxygenase-3 (ALOXE3) and 12 (R)-lipoxygenase (ALOX12B) are mutated in non-bullous congenital ichthyosiform erythroderma (NCIE) linked to chromosome 17p13.1. *Hum Mol Genet* 2002; 11: 107-113.
10. Krebsová A, Küster W, Lestringant GG, et al. Identification, by homozygosity mapping, of a novel locus for autosomal recessive congenital ichthyosis on chromosome 17p, and evidence for further genetic heterogeneity. *Am J Hum Genet* 2001; 69: 216-222.
11. Lesueur F, Bouadjar B, Lefèvre C, et al. Novel mutations in ALOX12B in patients with autosomal recessive congenital ichthyosis and evidence for genetic heterogeneity on chromosome 17p13. *J Invest Dermatol* 2007; 127: 829-834.
12. Lefèvre C, Bouadjar B, Ferrand V, et al. Mutations in a new cytochrome P450 gene in lamellar ichthyosis type 3. *Hum Mol Genet* 2006; 15: 767-776.
13. Israeli S, Khamaysi Z, Fuchs-Telem D, et al. A mutation in LIPN, encoding epidermal lipase N, causes a late-onset form of autosomal-recessive congenital ichthyosis. *Am J Hum Genet* 2011; 88: 482-487.
14. Lefevre C, Bouadjar B, Karaduman A, et al. Mutations in ichthyin a new gene on chromosome 5q33 in a new form of autosomal recessive congenital ichthyosis. *Hum Mol Genet* 2004; 13: 2473-2482.
15. Eckl KM, Tidhar R, Thiele H, et al. Impaired epidermal ceramide synthesis causes autosomal recessive congenital ichthyosis and reveals the importance of ceramide acyl chain length. *J Invest Dermatol* 2013; 133: 2202-2211.
16. Radner FP, Marrakchi S, Kirchmeier P, et al. Mutations in CERS3 cause autosomal recessive congenital ichthyosis in humans. *PLoS Genet* 2013; 9: e1003536.
17. Grall A, Guaguère E, Planchais S, et al. PNPLA1 mutations cause autosomal recessive congenital ichthyosis in golden retriever dogs and humans. *Nat Genet* 2012; 44: 140-147.
18. Chang PA, Sun YJ, Huang FF, et al. Identification of human patatin-like phospholipase domain-containing protein 1 and a mutant in human cervical cancer HeLa cells. *Mol Biol Rep* 2013; 40: 5597-5605.
19. Lake AC, Sun Y, Li JL, et al. Expression, regulation, and triglyceride hydrolase activity of Adiponutrin family members. *J Lipid Res* 2005; 46: 2477-2487.
20. Kienesberger PC, Oberer M, Lass A, Zechner R. Mammalian patatin domain containing proteins: A family with diverse lipolytic activities involved in multiple biological functions. *J Lipid Res.* 2009; 50 (Suppl): S63-S68.
21. Grond S, Eichmann TO, Dubrac S, et al. PNPLA1 deficiency in mice and humans leads to a defect in the synthesis of Omega-O-Acylceramides. *J Invest Dermatol* 2017; 137: 394-402.
22. Ohno Y, Kamiyama N, Nakamichi S, Kihara A. PNPLA1 is a transacylase essential for the generation of the skin barrier lipid ω -O-acylceramide. *Nat Commun* 2017; 8: 14610.
23. Hirabayashi T, Anjo T, Kaneko A, et al. PNPLA1 has a crucial role in skin barrier function by directing acylceramide biosynthesis. *Nat Commun* 2017; 8: 14609.
24. Fachal L, Rodriguez-Pazos L, Ginarte M, Carracedo A, Toribio J, Vega A. Identification of a novel PNPLA1 mutation in a Spanish family with autosomal recessive congenital ichthyosis. *Br J Dermatol* 2014; 170: 980-982.
25. Zimmer AD, Kim GJ, Hotz A, et al. Sixteen novel mutations in PNPLA1 in patients with autosomal recessive congenital ichthyosis reveal the importance of an extended patatin domain in PNPLA1 that is essential for proper human skin barrier function. *Br J Dermatol* 2017; 177: 445-455.
26. Lee E, Rahman OU, Khan M, et al. Whole exome analysis reveals a novel missense PNPLA1 variant that causes autosomal recessive congenital ichthyosis in a Pakistani family. *J Dermatol Sci* 2016; 82: 46-48.
27. Ahmad F, Ansar M, Mehmood S, et al. A novel missense variant in the PNPLA1 gene underlies congenital ichthyosis in three consanguineous families. *J Eur Acad Dermatol Venereol* 2016; 30: e210-e213.
28. Ohno Y, Nakamichi S, Ohkuni A, et al. Essential role of the cytochrome P450 CYP4F22 in the production of acylceramide, the key lipid for skin permeability barrier formation. *Proc Natl Acad Sci U S A* 2015; 112: 7707-7712.
29. Breiden B, Sandhoff K. The role of sphingolipid metabolism in cutaneous permeability barrier formation. *Biochim Biophys Acta* 2014; 1841: 441-452.
30. Vahidnezhad H, Youssefian L, Saeidian AH, et al. Gene-targeted next generation sequencing identifies PNPLA1 mutations in patients with a phenotypic spectrum of autosomal recessive congenital ichthyosis: The impact of consanguinity. *J Invest Dermatol* 2017; 137: 678-685.